3pjc - Revision history

OCA at 10:41, 21 February 2024

OCA — Wed, 21 Feb 2024 10:41:12 GMT

←Older revision		Revision as of 10:41, 21 February 2024
Line 3:		Line 3:
	<StructureSection load='3pjc' size='340' side='right'caption='[[3pjc]], [[Resolution\|resolution]] 2.20Å' scene=''>		<StructureSection load='3pjc' size='340' side='right'caption='[[3pjc]], [[Resolution\|resolution]] 2.20Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[3pjc]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/~~Human Human~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3PJC OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3PJC FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[3pjc]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3PJC OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3PJC FirstGlance]. <br>
-	</td></tr><tr id='~~ligand~~'><td class="sblockLbl"><b>[[~~Ligand~~\|~~Ligands~~:]]</b></td><td class="sblockDat" id="~~ligandDat~~">~~<scene name='pdbligand=PJC:3-(1H-INDOL-3-YL)-4~~-[~~2-(4-OXOPIPERIDIN-1-YL)-5-(TRIFLUOROMETHYL)PYRIMIDIN-4-YL~~]~~-1H-PYRROLE-~~2~~,5-DIONE'>PJC</scene>~~</td></tr>	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 2.2Å</td></tr>
-	<tr id='~~gene~~'><td class="sblockLbl"><b>[[~~Gene~~\|~~Gene~~:]]</b></td><td class="sblockDat"~~>JAK3 ([https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&~~id~~=9606 HUMAN])</td></tr>~~	+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=PJC:3-(1H-INDOL-3-YL)-4-[2-(4-OXOPIPERIDIN-1-YL)-5-(TRIFLUOROMETHYL)PYRIMIDIN-4-YL]-1H-PYRROLE-2,5-DIONE'>PJC</scene></td></tr>
-	~~<tr id='activity'><td class~~="~~sblockLbl~~"><~~b>Activity:</b></td><td class~~=~~"sblockDat"><span class~~=~~'plainlinks'>[https~~:~~//en.wikipedia.org/wiki/Non~~-~~specific_protein~~-~~tyrosine_kinase Non~~-~~specific protein~~-~~tyrosine kinase~~], ~~with EC number [https://www.brenda~~-~~enzymes.info/php/result_flat.php4?ecno=2.7.10.2 2.7.10.2]~~ </~~span~~></td></tr>	+
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3pjc FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3pjc OCA], [https://pdbe.org/3pjc PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3pjc RCSB], [https://www.ebi.ac.uk/pdbsum/3pjc PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3pjc ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3pjc FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3pjc OCA], [https://pdbe.org/3pjc PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3pjc RCSB], [https://www.ebi.ac.uk/pdbsum/3pjc PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3pjc ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
-	[[https://www.uniprot.org/uniprot/JAK3_HUMAN JAK3_HUMAN]] Defects in JAK3 are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-negative (T(-)B(+)NK(-) SCID) [MIM:[https://omim.org/entry/600802 600802]]. A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.<ref>PMID:15121872</ref> <ref>PMID:18250158</ref> <ref>PMID:15831699</ref> [:]<ref>PMID:7659163</ref> <ref>PMID:9354668</ref> <ref>PMID:9753072</ref> <ref>PMID:10982185</ref> <ref>PMID:14615376</ref>	+	[https://www.uniprot.org/uniprot/JAK3_HUMAN JAK3_HUMAN] Defects in JAK3 are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-negative (T(-)B(+)NK(-) SCID) [MIM:[https://omim.org/entry/600802 600802]. A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.<ref>PMID:15121872</ref> <ref>PMID:18250158</ref> <ref>PMID:15831699</ref> [:]<ref>PMID:7659163</ref> <ref>PMID:9354668</ref> <ref>PMID:9753072</ref> <ref>PMID:10982185</ref> <ref>PMID:14615376</ref>
	== Function ==		== Function ==
-	[[https://www.uniprot.org/uniprot/JAK3_HUMAN JAK3_HUMAN]] Non-receptor tyrosine kinase involved in various processes such as cell growth, development, or differentiation. Mediates essential signaling events in both innate and adaptive immunity and plays a crucial role in hematopoiesis during T-cells development. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors sharing the common subunit gamma such as IL2R, IL4R, IL7R, IL9R, IL15R and IL21R. Following ligand binding to cell surface receptors, phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins. Subsequently, phosphorylates the STATs proteins once they are recruited to the receptor. Phosphorylated STATs then form homodimer or heterodimers and translocate to the nucleus to activate gene transcription. For example, upon IL2R activation by IL2, JAK1 and JAK3 molecules bind to IL2R beta (IL2RB) and gamma chain (IL2RG) subunits inducing the tyrosine phosphorylation of both receptor subunits on their cytoplasmic domain. Then, STAT5A AND STAT5B are recruited, phosphorylated and activated by JAK1 and JAK3. Once activated, dimerized STAT5 translocates to the nucleus and promotes the transcription of specific target genes in a cytokine-specific fashion.<ref>PMID:8022485</ref> <ref>PMID:7662955</ref> <ref>PMID:20440074</ref>	+	[https://www.uniprot.org/uniprot/JAK3_HUMAN JAK3_HUMAN] Non-receptor tyrosine kinase involved in various processes such as cell growth, development, or differentiation. Mediates essential signaling events in both innate and adaptive immunity and plays a crucial role in hematopoiesis during T-cells development. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors sharing the common subunit gamma such as IL2R, IL4R, IL7R, IL9R, IL15R and IL21R. Following ligand binding to cell surface receptors, phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins. Subsequently, phosphorylates the STATs proteins once they are recruited to the receptor. Phosphorylated STATs then form homodimer or heterodimers and translocate to the nucleus to activate gene transcription. For example, upon IL2R activation by IL2, JAK1 and JAK3 molecules bind to IL2R beta (IL2RB) and gamma chain (IL2RG) subunits inducing the tyrosine phosphorylation of both receptor subunits on their cytoplasmic domain. Then, STAT5A AND STAT5B are recruited, phosphorylated and activated by JAK1 and JAK3. Once activated, dimerized STAT5 translocates to the nucleus and promotes the transcription of specific target genes in a cytokine-specific fashion.<ref>PMID:8022485</ref> <ref>PMID:7662955</ref> <ref>PMID:20440074</ref>
-	~~<div style="background-color:#fffaf0;">~~	+
-	~~== Publication Abstract from PubMed ==~~	+
-	We describe a synthetic approach toward the rapid modification of phenyl-indolyl maleimides and the discovery of potent Jak3 inhibitor 1 with high selectivity within the Jak kinase family. We provide a rationale for this unprecedented selectivity based on the X-ray crystal structure of an analogue of 1 bound to the ATP-binding site of Jak3. While equally potent compared to the Pfizer pan Jak inhibitor CP-690,550 (2) in an enzymatic Jak3 assay, compound 1 was found to be 20-fold less potent in cellular assays measuring cytokine-triggered signaling through cytokine receptors containing the common gamma chain (gammaC). Contrary to compound 1, compound 2 inhibited Jak1 in addition to Jak3. Permeability and cellular concentrations of compounds 1 and 2 were similar. As Jak3 always cooperates with Jak1 for signaling, we speculate that specific inhibition of Jak3 is not sufficient to efficiently block gammaC cytokine signal transduction required for strong immunosuppression.	+
-		+
-	Identification of a Potent Janus Kinase 3 Inhibitor with High Selectivity within the Janus Kinase Family.,Thoma G, Nuninger F, Falchetto R, Hermes E, Tavares GA, Vangrevelinghe E, Zerwes HG J Med Chem. 2010 Dec 14. PMID:21155605<ref>PMID:21155605</ref>	+
-		+
-	~~From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>~~	+
-	~~</div>~~	+
-	~~<div class="pdbe-citations 3pjc" style="background-color:#fffaf0;"></div~~>	+

	==See Also==		==See Also==
Line 29:		Line 19:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
-	[[Category: ~~Human~~]]	+	[[Category: Homo sapiens]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
-	~~[[Category: Non-specific protein-tyrosine kinase]]~~	+	[[Category: Kroemer M]]
-	[[Category: Kroemer, M]]	+	[[Category: Tavares GA]]
-	[[Category: Tavares~~, G A~~]]	+	[[Category: Thoma G]]
-	[[Category: Thoma, G]]	+	[[Category: Zerwes H-G]]
-	[[Category: Zerwes, H G]]	+
-	~~[[Category: Atp site kinase inhibitor]]~~	+
-	~~[[Category: Atp-binding]]~~	+
-	~~[[Category: Small molecule inhibitor]]~~	+
-	~~[[Category: Transferase]]~~	+
-	~~[[Category: Transferase-transferase inhibitor complex~~]]	+

OCA at 08:41, 25 May 2022

OCA — Wed, 25 May 2022 08:41:58 GMT

←Older revision		Revision as of 08:41, 25 May 2022
Line 1:		Line 1:

	==Crystal structure of JAK3 complexed with a potent ATP site inhibitor showing high selectivity within the Janus kinase family==		==Crystal structure of JAK3 complexed with a potent ATP site inhibitor showing high selectivity within the Janus kinase family==
-	<StructureSection load='3pjc' size='340' side='right' caption='[[3pjc]], [[Resolution\|resolution]] 2.20Å' scene=''>	+	<StructureSection load='3pjc' size='340' side='right'caption='[[3pjc]], [[Resolution\|resolution]] 2.20Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[3pjc]] is a 1 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3PJC OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=3PJC FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[3pjc]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3PJC OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3PJC FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=PJC:3-(1H-INDOL-3-YL)-4-[2-(4-OXOPIPERIDIN-1-YL)-5-(TRIFLUOROMETHYL)PYRIMIDIN-4-YL]-1H-PYRROLE-2,5-DIONE'>PJC</scene></td></tr>	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=PJC:3-(1H-INDOL-3-YL)-4-[2-(4-OXOPIPERIDIN-1-YL)-5-(TRIFLUOROMETHYL)PYRIMIDIN-4-YL]-1H-PYRROLE-2,5-DIONE'>PJC</scene></td></tr>
-	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">JAK3 ([~~http~~://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>	+	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">JAK3 ([https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
-	<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://en.wikipedia.org/wiki/Non-specific_protein-tyrosine_kinase Non-specific protein-tyrosine kinase], with EC number [~~http~~://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.2 2.7.10.2] </span></td></tr>	+	<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[https://en.wikipedia.org/wiki/Non-specific_protein-tyrosine_kinase Non-specific protein-tyrosine kinase], with EC number [https://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.2 2.7.10.2] </span></td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=3pjc FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3pjc OCA], [~~http~~://pdbe.org/3pjc PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=3pjc RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/3pjc PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=3pjc ProSAT]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3pjc FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3pjc OCA], [https://pdbe.org/3pjc PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3pjc RCSB], [https://www.ebi.ac.uk/pdbsum/3pjc PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3pjc ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
-	[[~~http~~://www.uniprot.org/uniprot/JAK3_HUMAN JAK3_HUMAN]] Defects in JAK3 are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-negative (T(-)B(+)NK(-) SCID) [MIM:[~~http~~://omim.org/entry/600802 600802]]. A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.<ref>PMID:15121872</ref> <ref>PMID:18250158</ref> <ref>PMID:15831699</ref> [:]<ref>PMID:7659163</ref> <ref>PMID:9354668</ref> <ref>PMID:9753072</ref> <ref>PMID:10982185</ref> <ref>PMID:14615376</ref>	+	[[https://www.uniprot.org/uniprot/JAK3_HUMAN JAK3_HUMAN]] Defects in JAK3 are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-negative (T(-)B(+)NK(-) SCID) [MIM:[https://omim.org/entry/600802 600802]]. A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.<ref>PMID:15121872</ref> <ref>PMID:18250158</ref> <ref>PMID:15831699</ref> [:]<ref>PMID:7659163</ref> <ref>PMID:9354668</ref> <ref>PMID:9753072</ref> <ref>PMID:10982185</ref> <ref>PMID:14615376</ref>
	== Function ==		== Function ==
-	[[~~http~~://www.uniprot.org/uniprot/JAK3_HUMAN JAK3_HUMAN]] Non-receptor tyrosine kinase involved in various processes such as cell growth, development, or differentiation. Mediates essential signaling events in both innate and adaptive immunity and plays a crucial role in hematopoiesis during T-cells development. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors sharing the common subunit gamma such as IL2R, IL4R, IL7R, IL9R, IL15R and IL21R. Following ligand binding to cell surface receptors, phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins. Subsequently, phosphorylates the STATs proteins once they are recruited to the receptor. Phosphorylated STATs then form homodimer or heterodimers and translocate to the nucleus to activate gene transcription. For example, upon IL2R activation by IL2, JAK1 and JAK3 molecules bind to IL2R beta (IL2RB) and gamma chain (IL2RG) subunits inducing the tyrosine phosphorylation of both receptor subunits on their cytoplasmic domain. Then, STAT5A AND STAT5B are recruited, phosphorylated and activated by JAK1 and JAK3. Once activated, dimerized STAT5 translocates to the nucleus and promotes the transcription of specific target genes in a cytokine-specific fashion.<ref>PMID:8022485</ref> <ref>PMID:7662955</ref> <ref>PMID:20440074</ref>	+	[[https://www.uniprot.org/uniprot/JAK3_HUMAN JAK3_HUMAN]] Non-receptor tyrosine kinase involved in various processes such as cell growth, development, or differentiation. Mediates essential signaling events in both innate and adaptive immunity and plays a crucial role in hematopoiesis during T-cells development. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors sharing the common subunit gamma such as IL2R, IL4R, IL7R, IL9R, IL15R and IL21R. Following ligand binding to cell surface receptors, phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins. Subsequently, phosphorylates the STATs proteins once they are recruited to the receptor. Phosphorylated STATs then form homodimer or heterodimers and translocate to the nucleus to activate gene transcription. For example, upon IL2R activation by IL2, JAK1 and JAK3 molecules bind to IL2R beta (IL2RB) and gamma chain (IL2RG) subunits inducing the tyrosine phosphorylation of both receptor subunits on their cytoplasmic domain. Then, STAT5A AND STAT5B are recruited, phosphorylated and activated by JAK1 and JAK3. Once activated, dimerized STAT5 translocates to the nucleus and promotes the transcription of specific target genes in a cytokine-specific fashion.<ref>PMID:8022485</ref> <ref>PMID:7662955</ref> <ref>PMID:20440074</ref>
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
	== Publication Abstract from PubMed ==		== Publication Abstract from PubMed ==
Line 24:		Line 24:

	==See Also==		==See Also==
-	*[[Janus kinase\|Janus kinase]]	+	*[[Janus kinase 3D structures\|Janus kinase 3D structures]]
	== References ==		== References ==
	<references/>		<references/>
Line 30:		Line 30:
	</StructureSection>		</StructureSection>
	[[Category: Human]]		[[Category: Human]]
		+	[[Category: Large Structures]]
	[[Category: Non-specific protein-tyrosine kinase]]		[[Category: Non-specific protein-tyrosine kinase]]
	[[Category: Kroemer, M]]		[[Category: Kroemer, M]]

OCA at 13:34, 4 August 2016

OCA — Thu, 04 Aug 2016 13:34:51 GMT

←Older revision		Revision as of 13:34, 4 August 2016
Line 1:		Line 1:
		+
	==Crystal structure of JAK3 complexed with a potent ATP site inhibitor showing high selectivity within the Janus kinase family==		==Crystal structure of JAK3 complexed with a potent ATP site inhibitor showing high selectivity within the Janus kinase family==
	<StructureSection load='3pjc' size='340' side='right' caption='[[3pjc]], [[Resolution\|resolution]] 2.20Å' scene=''>		<StructureSection load='3pjc' size='340' side='right' caption='[[3pjc]], [[Resolution\|resolution]] 2.20Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[3pjc]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/~~Homo_sapiens Homo sapiens~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3PJC OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3PJC FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[3pjc]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3PJC OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3PJC FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=PJC:3-(1H-INDOL-3-YL)-4-[2-(4-OXOPIPERIDIN-1-YL)-5-(TRIFLUOROMETHYL)PYRIMIDIN-4-YL]-1H-PYRROLE-2,5-DIONE'>PJC</scene></td></tr>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=PJC:3-(1H-INDOL-3-YL)-4-[2-(4-OXOPIPERIDIN-1-YL)-5-(TRIFLUOROMETHYL)PYRIMIDIN-4-YL]-1H-PYRROLE-2,5-DIONE'>PJC</scene></td></tr>
-	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">JAK3 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 ~~Homo sapiens~~])</td></tr>	+	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">JAK3 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
	<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Non-specific_protein-tyrosine_kinase Non-specific protein-tyrosine kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.2 2.7.10.2] </span></td></tr>		<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Non-specific_protein-tyrosine_kinase Non-specific protein-tyrosine kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.2 2.7.10.2] </span></td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3pjc FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3pjc OCA], [http://www.rcsb.org/pdb/explore.do?structureId=3pjc RCSB], [http://www.ebi.ac.uk/pdbsum/3pjc PDBsum]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3pjc FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3pjc OCA], [http://pdbe.org/3pjc PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=3pjc RCSB], [http://www.ebi.ac.uk/pdbsum/3pjc PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=3pjc ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
Line 20:		Line 21:
	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>		From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
	</div>		</div>
		+	<div class="pdbe-citations 3pjc" style="background-color:#fffaf0;"></div>

	==See Also==		==See Also==
Line 27:		Line 29:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
-	[[Category: ~~Homo sapiens~~]]	+	[[Category: Human]]
	[[Category: Non-specific protein-tyrosine kinase]]		[[Category: Non-specific protein-tyrosine kinase]]
	[[Category: Kroemer, M]]		[[Category: Kroemer, M]]

OCA at 06:38, 19 December 2014

OCA — Fri, 19 Dec 2014 06:38:48 GMT

←Older revision		Revision as of 06:38, 19 December 2014
Line 1:		Line 1:
-	~~{{STRUCTURE_3pjc\| PDB=3pjc \| SCENE= }}~~	+	==Crystal structure of JAK3 complexed with a potent ATP site inhibitor showing high selectivity within the Janus kinase family==
-	===Crystal structure of JAK3 complexed with a potent ATP site inhibitor showing high selectivity within the Janus kinase family===	+	<StructureSection load='3pjc' size='340' side='right' caption='[[3pjc]], [[Resolution\|resolution]] 2.20Å' scene=''>
-	~~{{ABSTRACT_PUBMED_21155605}}~~	+	== Structural highlights ==
		+	<table><tr><td colspan='2'>[[3pjc]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3PJC OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3PJC FirstGlance]. <br>
		+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=PJC:3-(1H-INDOL-3-YL)-4-[2-(4-OXOPIPERIDIN-1-YL)-5-(TRIFLUOROMETHYL)PYRIMIDIN-4-YL]-1H-PYRROLE-2,5-DIONE'>PJC</scene></td></tr>
		+	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">JAK3 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 Homo sapiens])</td></tr>
		+	<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Non-specific_protein-tyrosine_kinase Non-specific protein-tyrosine kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.2 2.7.10.2] </span></td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3pjc FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3pjc OCA], [http://www.rcsb.org/pdb/explore.do?structureId=3pjc RCSB], [http://www.ebi.ac.uk/pdbsum/3pjc PDBsum]</span></td></tr>
		+	</table>
		+	== Disease ==
		+	[[http://www.uniprot.org/uniprot/JAK3_HUMAN JAK3_HUMAN]] Defects in JAK3 are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-negative (T(-)B(+)NK(-) SCID) [MIM:[http://omim.org/entry/600802 600802]]. A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.<ref>PMID:15121872</ref> <ref>PMID:18250158</ref> <ref>PMID:15831699</ref> [:]<ref>PMID:7659163</ref> <ref>PMID:9354668</ref> <ref>PMID:9753072</ref> <ref>PMID:10982185</ref> <ref>PMID:14615376</ref>
		+	== Function ==
		+	[[http://www.uniprot.org/uniprot/JAK3_HUMAN JAK3_HUMAN]] Non-receptor tyrosine kinase involved in various processes such as cell growth, development, or differentiation. Mediates essential signaling events in both innate and adaptive immunity and plays a crucial role in hematopoiesis during T-cells development. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors sharing the common subunit gamma such as IL2R, IL4R, IL7R, IL9R, IL15R and IL21R. Following ligand binding to cell surface receptors, phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins. Subsequently, phosphorylates the STATs proteins once they are recruited to the receptor. Phosphorylated STATs then form homodimer or heterodimers and translocate to the nucleus to activate gene transcription. For example, upon IL2R activation by IL2, JAK1 and JAK3 molecules bind to IL2R beta (IL2RB) and gamma chain (IL2RG) subunits inducing the tyrosine phosphorylation of both receptor subunits on their cytoplasmic domain. Then, STAT5A AND STAT5B are recruited, phosphorylated and activated by JAK1 and JAK3. Once activated, dimerized STAT5 translocates to the nucleus and promotes the transcription of specific target genes in a cytokine-specific fashion.<ref>PMID:8022485</ref> <ref>PMID:7662955</ref> <ref>PMID:20440074</ref>
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	We describe a synthetic approach toward the rapid modification of phenyl-indolyl maleimides and the discovery of potent Jak3 inhibitor 1 with high selectivity within the Jak kinase family. We provide a rationale for this unprecedented selectivity based on the X-ray crystal structure of an analogue of 1 bound to the ATP-binding site of Jak3. While equally potent compared to the Pfizer pan Jak inhibitor CP-690,550 (2) in an enzymatic Jak3 assay, compound 1 was found to be 20-fold less potent in cellular assays measuring cytokine-triggered signaling through cytokine receptors containing the common gamma chain (gammaC). Contrary to compound 1, compound 2 inhibited Jak1 in addition to Jak3. Permeability and cellular concentrations of compounds 1 and 2 were similar. As Jak3 always cooperates with Jak1 for signaling, we speculate that specific inhibition of Jak3 is not sufficient to efficiently block gammaC cytokine signal transduction required for strong immunosuppression.

-	~~==Disease==~~	+	Identification of a Potent Janus Kinase 3 Inhibitor with High Selectivity within the Janus Kinase Family.,Thoma G, Nuninger F, Falchetto R, Hermes E, Tavares GA, Vangrevelinghe E, Zerwes HG J Med Chem. 2010 Dec 14. PMID:21155605<ref>PMID:21155605</ref>
-	~~[[http://www.uniprot.org/uniprot/JAK3_HUMAN JAK3_HUMAN]] Defects in JAK3 are~~ a ~~cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-negative (T(-)B(+)NK(-) SCID) [MIM:[http://omim~~.~~org/entry/600802 600802]]. A form of severe combined immunodeficiency (SCID)~~, ~~a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity~~, ~~leukopenia~~, ~~and low or absent antibody levels. Patients present in infancy recurrent~~, ~~persistent infections by opportunistic organisms~~. ~~The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development~~.~~<ref>~~PMID:~~15121872</ref><ref>PMID:18250158</ref><ref>PMID:15831699</ref>[:]<ref>PMID:7659163</ref><ref>PMID:9354668</ref><ref>PMID:9753072</ref><ref>PMID:10982185</ref>~~<ref>PMID:~~14615376~~</ref>	+

-	~~==Function==~~	+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-	~~[[http://www.uniprot.org/uniprot~~/~~JAK3_HUMAN JAK3_HUMAN]] Non-receptor tyrosine kinase involved in various processes such as cell growth~~, ~~development, or differentiation. Mediates essential signaling events in both innate and adaptive immunity and plays~~ a crucial role in hematopoiesis during T-cells development. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors sharing the common subunit gamma such as IL2R, IL4R, IL7R, IL9R, IL15R and IL21R. Following ligand binding to cell surface receptors, phosphorylates specific tyrosine residues on the cytoplasmic tails of the ~~receptor, creating docking sites for STATs proteins~~. ~~Subsequently, phosphorylates the STATs proteins once they are recruited to the receptor~~. Phosphorylated STATs then form homodimer or heterodimers and translocate to the nucleus to activate gene transcription. For example, upon IL2R activation by IL2, JAK1 and JAK3 molecules bind to IL2R beta (IL2RB) and gamma chain (IL2RG) subunits inducing the tyrosine phosphorylation of both receptor subunits on their cytoplasmic domain. Then, STAT5A AND STAT5B are recruited, phosphorylated and activated by JAK1 and JAK3. Once activated, dimerized STAT5 translocates to the nucleus and promotes the transcription of specific target genes in a cytokine-specific fashion.<~~ref~~>~~PMID:8022485</ref><ref>PMID:7662955</ref><ref>PMID:20440074~~</~~ref~~>	+	</div>

-	==~~About this Structure~~==	+	==See Also==
-	[[~~3pjc~~]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3PJC OCA].	+	*[[Janus kinase\|Janus kinase]]
-		+	== References ==
-	==~~Reference~~==	+	<references/>
-	~~<ref group="xtra">PMID:021155605</ref>~~<references ~~group="xtra"~~/><~~references~~/>	+	__TOC__
		+	</StructureSection>
	[[Category: Homo sapiens]]		[[Category: Homo sapiens]]
	[[Category: Non-specific protein-tyrosine kinase]]		[[Category: Non-specific protein-tyrosine kinase]]
-	[[Category: Kroemer, M.]]	+	[[Category: Kroemer, M]]
-	[[Category: Tavares, G A.]]	+	[[Category: Tavares, G A]]
-	[[Category: Thoma, G.]]	+	[[Category: Thoma, G]]
-	[[Category: Zerwes, H G.]]	+	[[Category: Zerwes, H G]]
	[[Category: Atp site kinase inhibitor]]		[[Category: Atp site kinase inhibitor]]
	[[Category: Atp-binding]]		[[Category: Atp-binding]]

OCA at 19:30, 24 March 2013

OCA — Sun, 24 Mar 2013 19:30:03 GMT

←Older revision		Revision as of 19:30, 24 March 2013
Line 1:		Line 1:
-	[[Image:3pjc.png\|left\|200px]]
-
-	<!--
-	The line below this paragraph, containing "STRUCTURE_3pjc", creates the "Structure Box" on the page.
-	You may change the PDB parameter (which sets the PDB file loaded into the applet)
-	or the SCENE parameter (which sets the initial scene displayed when the page is loaded),
-	or leave the SCENE parameter empty for the default display.
-	-->
	{{STRUCTURE_3pjc\| PDB=3pjc \| SCENE= }}		{{STRUCTURE_3pjc\| PDB=3pjc \| SCENE= }}
-
	===Crystal structure of JAK3 complexed with a potent ATP site inhibitor showing high selectivity within the Janus kinase family===		===Crystal structure of JAK3 complexed with a potent ATP site inhibitor showing high selectivity within the Janus kinase family===
		+	{{ABSTRACT_PUBMED_21155605}}

		+	==Disease==
		+	[[http://www.uniprot.org/uniprot/JAK3_HUMAN JAK3_HUMAN]] Defects in JAK3 are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-negative (T(-)B(+)NK(-) SCID) [MIM:[http://omim.org/entry/600802 600802]]. A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.<ref>PMID:15121872</ref><ref>PMID:18250158</ref><ref>PMID:15831699</ref>[:]<ref>PMID:7659163</ref><ref>PMID:9354668</ref><ref>PMID:9753072</ref><ref>PMID:10982185</ref><ref>PMID:14615376</ref>

-	<!--	+	==Function==
-	~~The line below this paragraph~~, ~~{{ABSTRACT_PUBMED_21155605}}~~, ~~adds~~ the ~~Publication Abstract~~ to the ~~page~~	+	[[http://www.uniprot.org/uniprot/JAK3_HUMAN JAK3_HUMAN]] Non-receptor tyrosine kinase involved in various processes such as cell growth, development, or differentiation. Mediates essential signaling events in both innate and adaptive immunity and plays a crucial role in hematopoiesis during T-cells development. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors sharing the common subunit gamma such as IL2R, IL4R, IL7R, IL9R, IL15R and IL21R. Following ligand binding to cell surface receptors, phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins. Subsequently, phosphorylates the STATs proteins once they are recruited to the receptor. Phosphorylated STATs then form homodimer or heterodimers and translocate to the nucleus to activate gene transcription. For example, upon IL2R activation by IL2, JAK1 and JAK3 molecules bind to IL2R beta (IL2RB) and gamma chain (IL2RG) subunits inducing the tyrosine phosphorylation of both receptor subunits on their cytoplasmic domain. Then, STAT5A AND STAT5B are recruited, phosphorylated and activated by JAK1 and JAK3. Once activated, dimerized STAT5 translocates to the nucleus and promotes the transcription of specific target genes in a cytokine-specific fashion.<ref>PMID:8022485</ref><ref>PMID:7662955</ref><ref>PMID:20440074</ref>
-	(~~as it appears~~ on ~~PubMed at http://www~~.~~pubmed~~.~~gov)~~, ~~where 21155605 is~~ the ~~PubMed ID number.~~	+
-	-->	+
-	~~{{ABSTRACT_PUBMED_21155605}}~~	+

	==About this Structure==		==About this Structure==
Line 22:		Line 13:

	==Reference==		==Reference==
-	<ref group="xtra">PMID:021155605</ref><references group="xtra"/>	+	<ref group="xtra">PMID:021155605</ref><references group="xtra"/><references/>
	[[Category: Homo sapiens]]		[[Category: Homo sapiens]]
	[[Category: Non-specific protein-tyrosine kinase]]		[[Category: Non-specific protein-tyrosine kinase]]

OCA at 04:59, 28 September 2011

OCA — Wed, 28 Sep 2011 04:59:43 GMT

←Older revision		Revision as of 04:59, 28 September 2011
Line 1:		Line 1:
-	[[Image:3pjc.~~jpg~~\|left\|200px]]	+	[[Image:3pjc.png\|left\|200px]]

	<!--		<!--
Line 22:		Line 22:

	==Reference==		==Reference==
-	<ref group="xtra">PMID:~~21155605~~</ref><references group="xtra"/>	+	<ref group="xtra">PMID:021155605</ref><references group="xtra"/>
	[[Category: Homo sapiens]]		[[Category: Homo sapiens]]
	[[Category: Non-specific protein-tyrosine kinase]]		[[Category: Non-specific protein-tyrosine kinase]]

OCA: Protected "3pjc" [edit=sysop:move=sysop]

OCA — Wed, 29 Dec 2010 18:40:37 GMT

Protected "3pjc" [edit=sysop:move=sysop]

←Older revision

Revision as of 18:40, 29 December 2010

OCA at 18:40, 29 December 2010

OCA — Wed, 29 Dec 2010 18:40:34 GMT

←Older revision		Revision as of 18:40, 29 December 2010
Line 1:		Line 1:
-	~~'''Unreleased structure'''~~	+	[[Image:3pjc.jpg\|left\|200px]]

-	The ~~entry 3pjc~~ is ~~ON HOLD~~ ~~until Paper Publication~~	+	<!--
		+	The line below this paragraph, containing "STRUCTURE_3pjc", creates the "Structure Box" on the page.
		+	You may change the PDB parameter (which sets the PDB file loaded into the applet)
		+	or the SCENE parameter (which sets the initial scene displayed when the page is loaded),
		+	or leave the SCENE parameter empty for the default display.
		+	-->
		+	{{STRUCTURE_3pjc\| PDB=3pjc \| SCENE= }}

-	~~Authors: Tavares, G.A., Thoma, G., Zerwes, H.-G., Kroemer, M.~~	+	===Crystal structure of JAK3 complexed with a potent ATP site inhibitor showing high selectivity within the Janus kinase family===

-	Description: Crystal structure of JAK3 complexed with a potent ATP site inhibitor showing high selectivity within the Janus kinase family

-	~~''Page seeded by~~ [http://oca.weizmann.ac.il/oca OCA ] ~~on Wed Dec 8 11~~:32:~~03 2010''~~	+	<!--
		+	The line below this paragraph, {{ABSTRACT_PUBMED_21155605}}, adds the Publication Abstract to the page
		+	(as it appears on PubMed at http://www.pubmed.gov), where 21155605 is the PubMed ID number.
		+	-->
		+	{{ABSTRACT_PUBMED_21155605}}
		+
		+	==About this Structure==
		+	[[3pjc]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3PJC OCA].
		+
		+	==Reference==
		+	<ref group="xtra">PMID:21155605</ref><references group="xtra"/>
		+	[[Category: Homo sapiens]]
		+	[[Category: Non-specific protein-tyrosine kinase]]
		+	[[Category: Kroemer, M.]]
		+	[[Category: Tavares, G A.]]
		+	[[Category: Thoma, G.]]
		+	[[Category: Zerwes, H G.]]
		+	[[Category: Atp site kinase inhibitor]]
		+	[[Category: Atp-binding]]
		+	[[Category: Small molecule inhibitor]]
		+	[[Category: Transferase]]
		+	[[Category: Transferase-transferase inhibitor complex]]

OCA at 08:19, 8 December 2010

OCA — Wed, 08 Dec 2010 08:19:59 GMT

←Older revision		Revision as of 08:19, 8 December 2010
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 3pjc is ON HOLD	+	The entry 3pjc is ON HOLD until Paper Publication

	Authors: Tavares, G.A., Thoma, G., Zerwes, H.-G., Kroemer, M.		Authors: Tavares, G.A., Thoma, G., Zerwes, H.-G., Kroemer, M.

-	Description: Crystal structure of JAK3 complexed with a potent ATP site inhibitor ~~with~~ high selectivity within the Janus kinase family	+	Description: Crystal structure of JAK3 complexed with a potent ATP site inhibitor showing high selectivity within the Janus kinase family

-	''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on ~~Thu Nov 18 00~~:34:55 2010''	+	''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Wed Dec 8 11:32:03 2010''

OCA: New page: '''Unreleased structure''' The entry 3pjc is ON HOLD Authors: Tavares, G.A., Thoma, G., Zerwes, H.-G., Kroemer, M. Description: Crystal structure of JAK3 complexed with a potent ATP si...

OCA — Wed, 17 Nov 2010 21:23:40 GMT

New page: '''Unreleased structure''' The entry 3pjc is ON HOLD Authors: Tavares, G.A., Thoma, G., Zerwes, H.-G., Kroemer, M. Description: Crystal structure of JAK3 complexed with a potent ATP si...

New page

'''Unreleased structure'''

The entry 3pjc is ON HOLD

Authors: Tavares, G.A., Thoma, G., Zerwes, H.-G., Kroemer, M.

Description: Crystal structure of JAK3 complexed with a potent ATP site inhibitor with high selectivity within the Janus kinase family

''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Nov 18 00:34:55 2010''